G1 Therapeutics/ US3621LQ1099 /
| 2024-05-03 9:59:32 PM | Chg. +0.05 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 4.49USD | +1.13% | 9,507 Turnover: 43,384.75 |
-Bid Size: - | -Ask Size: - | 4.69 | 4.49 |
GlobeNewswire
05-01
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
05-01
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire
05-01
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
GlobeNewswire
04-17
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1...
GlobeNewswire
04-04
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire
04-01
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
03-01
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
02-28
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlig...
GlobeNewswire
02-27
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
GlobeNewswire
02-15
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business ...
GlobeNewswire
02-12
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breas...
GlobeNewswire
01-08
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
01-03
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
01-02
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2023-12-05
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Tril...
GlobeNewswire
2023-12-01
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2023-11-30
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
GlobeNewswire
2023-11-01
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
GlobeNewswire
2023-10-27
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and M...
GlobeNewswire
2023-10-18
G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from...
GlobeNewswire
2023-10-18
G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on Nove...
GlobeNewswire
2023-10-16
G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
GlobeNewswire
2023-09-05
G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
